Celldex Therapeutics (NASDAQ:CLDX) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX - Free Report) in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $80.00 price target on the biopharmaceutical company's stock.

Other equities research analysts have also recently issued research reports about the stock. Guggenheim upped their price objective on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a buy rating in a research report on Tuesday, February 27th. TD Cowen started coverage on shares of Celldex Therapeutics in a research report on Wednesday, December 20th. They set an outperform rating for the company. Finally, Cantor Fitzgerald reissued an overweight rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Friday, March 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $66.00.

Celldex Therapeutics Stock Up 2.7 %

Shares of CLDX traded up $1.03 during midday trading on Wednesday, reaching $39.63. 908,995 shares of the stock were exchanged, compared to its average volume of 906,799. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18. The company has a market cap of $2.22 billion, a P/E ratio of -13.58 and a beta of 1.49. The stock's 50 day simple moving average is $41.98 and its 200 day simple moving average is $35.68.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The business had revenue of $4.13 million during the quarter, compared to analysts' expectations of $1.20 million. As a group, analysts predict that Celldex Therapeutics will post -2.85 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CLDX. Wellington Management Group LLP increased its position in Celldex Therapeutics by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company's stock valued at $149,484,000 after purchasing an additional 300,406 shares during the period. GSA Capital Partners LLP lifted its holdings in shares of Celldex Therapeutics by 192.0% in the 3rd quarter. GSA Capital Partners LLP now owns 44,716 shares of the biopharmaceutical company's stock worth $1,231,000 after purchasing an additional 29,404 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Celldex Therapeutics in the 4th quarter worth $994,000. SG Americas Securities LLC lifted its holdings in shares of Celldex Therapeutics by 1,481.7% in the 3rd quarter. SG Americas Securities LLC now owns 78,011 shares of the biopharmaceutical company's stock worth $2,147,000 after purchasing an additional 73,079 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Celldex Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,547 shares of the biopharmaceutical company's stock worth $9,950,000 after purchasing an additional 10,818 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.